Adds shares in paragraph 3, details throughout

May 29 (Reuters) - Replimune REPL.O said on Friday it it has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental skin cancer drug after the regulator twice declined to approve the therapy.

The company said it will resubmit the application for vusolimogene oderparepvec in the coming days.

Shares of the company jumped nearly 74% in premarket trading.

Replimune said the FDA has indicated it will treat the resubmission as an urgent matter upon receipt and will prioritize its review.